Dysautonomia in post-covid-19 condition appears to affect a significant number ofpatients, with reports raising the incidence up to 61%, having an overlap with myalgicencephalomyelitis/ chronic fatigue syndrome. Quality of life and daily function issignificantly impacted and conservative management interventions, despite the lack ofhigh quality evidence up to now, are needed to ameliorate disability. 50 adults with adysautonomia post-covid-19 diagnosis based on the Ewing battery and a NASA lean test willbe enrolled in a randomized single blinded controlled trial with a crossover design.Feasibility and lack of definite dysautonomia diagnosis will be the primary out-comes,while secondary outcomes will be health-related, clinical and cardiopulmonary exercisetest indicators. Safety and acceptance will also be checked, primarily excludingparticipants with post exertional malaise. The Long-CoViD patients Causal Diagnosis andRehabilitation study in patients with Dysautonomia (LoCoDiRE-Dys) study intervention willconsist of an educational module, breathing retraining and an individualized exerciseintervention of biweekly sessions for two months with regular assessment of both groups.LoCoDiRe- Dys aims to be the first post-covid-19 randomized study in people withdysautonomia offering a multimodal intervention both in diagnosis and management